The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and celebrated the launch of a unified organization that combines JAX’s strengths in mouse genetics with NYSCF’s high‑throughput human stem‑cell and automation platforms. Leaders including JAX CEO Lon Cardon and former NIH director Francis Collins attended the launch and framed the union as a new engine for translational genomics. Executives cited examples—like a rapid custom gene‑therapy case that reached a patient in seven months—to illustrate how integrated platforms could speed bench‑to‑bedside translation. The unified nonprofit aims to scale reproducible stem‑cell science, automation and genetic models to support preclinical discovery. The consolidation underscores how nonprofit research infrastructure providers are reshaping translational pipelines by aligning genetic model expertise with scalable human cell platforms.